Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fu Jen Catholic University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
In this study, the improvement of the clinical status of early-stage non-alcoholic fatty liver disease (NAFLD) patients after the probiotic intervention will be assessed. And the mechanism of probiotics to prevent the progression of illness would be investigated. The chronic inflammation status, systemic oxidative stress, metabolism of carbohydrates and lipid, and gut microbiota of NAFLD patients will also be analyzed.
Uncontrolled NAFLD evolves in Non-Alcoholic SteatoHepatitis (NASH), cirrhosis and liver cancer. Early intervention to prevent the progression of illness of NAFLD is very important. From 2005 to 2018, 15 clinical trials concluded that multiple-strain probiotics significantly reduced the liver inflammation index and blood lipids in NAFLD patients. Many reports indicated that NAFLD-associated risk factors, such as chronic inflammation, oxidative stress, insulin resistance, dyslipidemia, and obesity are closely correlated with gut microbiota. Some substances (such as endotoxin and alcohol) produced by harmful gut bacteria caused the progression of the illness of NAFLD.
Three strains are Genmont® Normal Lactobacillus (GMNL) which were divided from natural environments, included Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive). They are all isolated from the gastrointestinal tract of healthy Taiwanese and were known as common food material worldwide. The previous clinical research on probiotic consumption in type 2 Diabetes mellitus patients under normal drug treatment was conducted in Changhua Christian Hospital. Results showed that L. reuteri GMNL-263 was able to stabilize the weight and blood pressure of patients. L. reuteri GMNL-89 had a stable effect on glycated hemoglobin. There was no adverse reaction when probiotics combining with type 2 diabetes drugs. Meanwhile, L. rhamnosus GMNL-74 was observed to reduce weight gain in obese mice. In this clinical study, The anti-liver inflammation effect of consumption of Lactobacillus sachet in NAFLD patients will be demonstrated at baseline, 3 months and 6 months. In this clinical study, the anti-liver inflammation effect of consumption of Lactobacillus sachet in NAFLD patients will be demonstrated at baseline, 3 months and 6 months to understand the impact of the probiotics on NAFLD. Since the treatment of fatty liver should focus on controlling weight, blood sugar, and blood fat, the relevant clinical indexes will also be investigated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo group | Placebo Comparator | Subjects received two placebo sachets per day |
|
| Probiotic group | Experimental | Subjects received two probiotic sachets per day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Other | Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum ALT (Alanine Aminotransferase) level at baseline | The number of patients will be enrolled with the concentration of ALT (Alanine Aminotransferase) ranging from 60 to 300 U/mL in serum. | baseline |
| Change from baseline in Serum ALT (Alanine Aminotransferase) level at 3-months | Fasting blood samples will be collected to examine the variation of ALT (Alanine Aminotransferase). | 3-months |
| Change from baseline in Serum ALT (Alanine Aminotransferase) level at 6-months | Fasting blood samples will be collected to examine the variation of ALT (Alanine Aminotransferase). | 6-months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in BMI (Body Mass index) at 3-months | BMI will be calculated with weight and height combined in kg/m^2, the weight will be measured in kilograms and the height will be recorded in centimeters. | 3-months |
| Change from baseline in BMI (Body Mass index) at 6-months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chi-Yang Chang, PhD | Fu Jen Catholic University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fu Jen Catholic University Hospital | New Taipei City | Taiwan |
Not provided
| ID | Term |
|---|---|
| D065626 | Non-alcoholic Fatty Liver Disease |
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| D019936 | Probiotics |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
Randomized Controlled Trail
Not provided
Not provided
Not provided
| Probiotics | Dietary Supplement | Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive). |
|
|
BMI will be calculated with weight and height combined in kg/m^2, the weight will be measured in kilograms and the height will be recorded in centimeters. |
| 6-months |
| Change from baseline in Waist and hip circumference at 3-months | Waist and hip circumference will take down in centimeters. | 3-months |
| Change from baseline in Waist and hip circumference at 6-months | Waist and hip circumference will take down in centimeters. | 6-months |
| Change from baseline in blood pressure at 3-months | The unit of measurement of blood pressure is mmHg. Both systolic and diastolic blood pressure will be measured. | 3-months |
| Change from baseline in blood pressure at 6-months | The unit of measurement of blood pressure is mmHg. Both systolic and diastolic blood pressure will be measured. | 6-months |
| Change from baseline in the progress of the non-alcoholic fatty liver disease at 3-months | Utilizing abdominal ultrasound to detect the progress of Non-alcoholic fatty liver disease (NAFLD). | 3-months |
| Change from baseline in the progress of the non-alcoholic fatty liver disease at 6-months | Utilizing abdominal ultrasound to detect the progress of Non-alcoholic fatty liver disease (NAFLD). | 6-months |
| Change from baseline in levels of AST(Aspartate Aminotransferase) at 3-months | Fasting blood samples will be collected to examine changes from baseline in AST(Aspartate Aminotransferase) in IU/L at 3-months. | 3-months |
| Change from baseline in levels of AST(Aspartate Aminotransferase) at 6-months | Fasting blood samples will be collected to examine changes from baseline in AST(Aspartate Aminotransferase) in IU/L at 6-months. | 6-months |
| Change from baseline in the level of γ-GT (γ-Glutamyl Transpeptidase) at 3-months | Fasting blood samples will be collected to examine changes from baseline in γ-GT (γ-Glutamyl Transpeptidase) in IU/L at 3-months. | 3-months |
| Change from baseline in the level of γ-GT (γ-Glutamyl Transpeptidase) at 6-months | Fasting blood samples will be collected to examine changes from baseline in γ-GT (γ-Glutamyl Transpeptidase) in IU/L at 6-months. | 6-months |
| Change from baseline in the level of BUN (Blood Urea Nitrogen) at 3-months | Fasting blood samples will be collected to examine changes in BUN(Blood Urea Nitrogen) from baseline in mg/dL at 3-months. | 3-months |
| Change from baseline in the level of BUN (Blood Urea Nitrogen) at 6-months | Fasting blood samples will be collected to examine changes from baseline in BUN(Blood Urea Nitrogen) in mg/dL at 6-months. | 6-months |
| Change from baseline in the level of CRE (Creatinine) at 3-months | Fasting blood samples will be collected to examine changes from baseline in CRE(Creatinine) in mg/dL at 3-months. | 3-months |
| Change from baseline in the level of CRE (Creatinine) at 6-months | Fasting blood samples will be collected to examine changes from baseline in CRE(Creatinine) in mg/dL at 6-months. | 6-months |
| Change from baseline in levels of FBS (Fasting Blood Sugar) at 3-months | Fasting blood samples will be collected to examine changes from baseline in FBS(Fasting Blood Sugar) in mg/dL at 6-months. | 3-months |
| Change from baseline in the level of FBS (Fasting Blood Sugar) at 6-months | Fasting blood samples will be collected to examine changes from baseline in FBS(Fasting Blood Sugar) in mg/dL at 6-months. | 6-months |
| Change from baseline in levels of HbA1c (Hemoglobin A1C) at 3-months | Fasting blood samples will be collected to investigate the levels of HbA1c(Hemoglobin A1C) in % from baseline at 3-months. | 3-months |
| Change from baseline in levels of HbA1c (Hemoglobin A1C) at 6-months | Fasting blood samples will be collected to investigate the levels of HbA1c(Hemoglobin A1C) in % from baseline at 6-months. | 6-months |
| Change from baseline in levels of serum insulin at baseline | Fasting blood samples will be collected to examine variation in serum insulin in uIU/mL from baseline at 3-months. | 3-months |
| Change from 3-months in levels of serum insulin at baseline | Fasting blood samples will be collected to examine variation in serum insulin in uIU/mL from baseline at 6-months. | 6-months |
| Change from Baseline in levels of HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) at 3-months | HOMA-IR(Homeostatic Model Assessment for Insulin Resistance) will be calculated with insulin and glucose. (HOMA-IR=(insulin (mIU/L) and glucose (mg/dl))/405) | 3-months |
| Change from baseline in levels of HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) at 6-months | HOMA-IR(Homeostatic Model Assessment for Insulin Resistance) will be calculated with insulin and glucose. (HOMA-IR=(insulin (mIU/L) and glucose (mg/dl))/405) | 6-months |
| Change from baseline in levels of TC (Total Cholesterol) at 3-months | Fasting blood samples will be collected to examine variation from baseline in (Total Cholesterol) in mg/dL at 3-months. | 3-months |
| Change from baseline in levels of TC (Total Cholesterol) at 6-months | Fasting blood samples will be collected to examine variation from baseline in (Total Cholesterol) in mg/dL from baseline at 6-months. | 6-months |
| Change from baseline in level of HDL (High density lipoprotein) at 3-months | Fasting blood samples will be collected to examine variation from baseline in HDL(High density lipoprotein) in mg/dL at 3-months. | 3-months |
| Change from baseline in level of HDL (High density lipoprotein) at 6-months | Fasting blood samples will be collected to examine variation from baseline in HDL(High density lipoprotein) in mg/dL at 6-months. | 6-months |
| Change from baseline in level of LDL (Low density lipoprotein) at 3-months | Fasting blood samples will be collected to examine variation from baseline in LDL(Low density lipoprotein) in mg/dL at 3-months. | 3-months |
| Change from baseline in level of LDL (Low density lipoprotein) at 6-months | Fasting blood samples will be collected to examine variation from baseline in LDL(Low density lipoprotein) in mg/dL at 6-months. | 6-months |
| Change from baseline in level of TG (Triglyceride) at 3-months | Fasting blood samples will be collected to examine variation from baseline in TG(Triglyceride) in mg/dL to 3-months. | 3-months |
| Change from baseline in level of TG (Triglyceride) at 6-months | Fasting blood samples will be collected to examine variation from baseline in TG(Triglyceride) in mg/dL to 6-months. | 6-months |
| Change from baseline in level of hs-CRP (high-sensitivity C-reactive protein) at 3-months | Blood samples will be collected to examine variation from baseline in hs-CRP(high-sensitivity C-reactive protein) in mg/dL at 3-months. | 3-months |
| Change from baseline in level of hs-CRP (high-sensitivity C-reactive protein) at 6-months | Blood samples will be collected to examine variation from baseline in hs-CRP(high-sensitivity C-reactive protein) in mg/dL at 6-months. | 6-months |
| Change from baseline in level of TNF-α (Tumor necrosis factor-α) at 3-months | Blood samples will be collected to examine variation from baseline in TNF-α (Tumor necrosis factor-α) in pg/mL at 3-months. | 3-months |
| Change from baseline in level of TNF-α (Tumor necrosis factor-α) at 6-months | Blood samples will be collected to examine variation from baseline in TNF-α (Tumor necrosis factor-α) in pg/mL at 6-months. | 6-months |
| Change from baseline in level of IL-1β (Interleukin-1 β) at 3-months | Blood samples will be collected to examine variation from baseline in IL-1β(Interleukin-1 β) in pg/mL at 3-months. | 3-months |
| Change from baseline in level of IL-1β (Interleukin-1 β) at 6-months | Blood samples will be collected to examine variation from baseline in IL-1β(Interleukin-1 β) in pg/mL at 6-months. | 6-months |
| Change from baseline in level of IL-6 (Interleukin-6) at 3-months | Blood samples will be collected to examine variation from baseline in IL-6(Interleukin-6) in pg/mL at 3-months. | 3-months |
| Change from baseline in level of IL-6 (Interleukin-6) at 6-months | Blood samples will be collected to examine variation from baseline in IL-6(Interleukin-6) in pg/mL at 6-months. | 6-months |
| Change from baseline in level of LPS (Lipopolysaccharides) at 3-months | Blood samples will be collected to examine variation from baseline in LPS(Lipopolysaccharides) in mg/dL at 3-months. | 3-months |
| Change from baseline in level of LPS (Lipopolysaccharides) at 6-months | Blood samples will be collected to examine variation from baseline in LPS(Lipopolysaccharides) in mg/dL at 6-months. | 6-months |
| Change from baseline in level of Leptin at 3-months | Blood samples will be collected to examine variation from baseline in Leptin in pg/mL at 3-months. | 3-months |
| Change from baseline in level of Leptin at 6-months | Blood samples will be collected to examine variation from baseline in Leptin in pg/mL at 6-months. | 6-months |
| Change from baseline in level of Adiponectin at 3-months | Blood samples will be collected to examine variation from baseline in Adiponectin in pg/mL at 3-months. | 3-months |
| Change from baseline in level of Adiponectin at 6-months | Blood samples will be collected to examine variation from baseline in Adiponectin in pg/mL at 6-months. | 6-months |
| Change from baseline in the level of SCFA (Short Chain Fatty Acids) at 6-months | Blood samples will be collected to examine variation from baseline in SCFA (Short Chain Fatty Acids) in ug/mL at 6-months. | 6-months |
| Change from baseline in the level of TMAO (Trimethylamine N-oxide) at 6-months | Blood samples will be collected to examine variation from baseline in TMAO (Trimethylamine N-oxide) in μmol/L at 6-months. | 6-months |
| Change from baseline in Self-questionnaire of Diet and lifestyle assessments at 6-months | The questionnaire will record dietary/drink preferences and other habits by the subject himself /herself, the content of the questionnaire includes vegetarian or not, the frequency if intake of tea, dairy, coffee or yakult intake, smoking habits, betel nuts intake and alcohol consumption. | 6-months |
| Change from baseline in self-record of the International physical activity questionary (IPAQ) in physical assessment at 6-months | The questionnaire will be finished to record the laborious activity by the subject himself /herself before and after the treatment. | 6-months |
| Change from baseline in gut microbiota at 6-months | The analysis of Gut microbiota will utilize DNA sequencing to investigate the intestinal microbiota through stool samples in subjects with NAFLD at 6-months. | 6-months |
| D008722 | Methods |
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |